Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV
Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY - ppt download
Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect
Ritonavir (Norvir)
Ritonavir Increases levels of Schering HCV Protease Inhibitor SCH503034
Summary of unboosted and ritonavir-boosted PI dose regimens | Download Table
HIV-Protease Inhibitors: Viral Resistance, Pharmacokinetic Boosting, and Medication Adherence
Ritonavir (CAS 155213-67-5): R&D Systems
Ritonavir 155213-67-5 | TCI AMERICA
Solved A study for the treatment of patients with HIV-1 was | Chegg.com
IJMS | Free Full-Text | The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms | Biochemistry
High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment | Scientific Reports
Boosted protease inhibitor and lamivudine provides effective maintenance treatment | aidsmap
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19
Ritonavir - Wikipedia
HIV Antiretroviral Pharmacokinetic Boosters - Ritonavir ... | GrepMed
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar
HIV-Protease Inhibitors: Viral Resistance, Pharmacokinetic Boosting, and Medication Adherence
Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro
How Ritonavir acts as booster drug - YouTube
Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers | SpringerLink
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19
Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression - ScienceDirect
Ritonavir (Norvir) - Indications, Dose, Side effects
